{
  "PMC": "4961897",
  "DOI": "10.1016/j.dadm.2016.05.001",
  "PMID": "27489878",
  "PMCID": "PMC4961897",
  "title": "Untangling tau imaging.",
  "year": 2016,
  "source_url": "https://europepmc.org/article/PMC/PMC4961897",
  "source": "MED",
  "abstract_text": "In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials.",
  "full_text": "Alzheimers Dement (Amst) Alzheimers Dement (Amst) Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring 2352-8729 Elsevier 4961897 S2352-8729(16)30012-4 10.1016/j.dadm.2016.05.001 Neuroimaging Untangling tau imaging Villemagne Victor L. victorlv@unimelb.edu.au a b c ∗ Okamura Nobuyuki d Rowe Christopher C. a c a Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Melbourne, Australia b The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia c Department of Medicine, The University of Melbourne, Melbourne, Australia d Department of Pharmacology, Tohoku University, Sendai, Japan ∗ Corresponding author. Tel.: +61-394963321; Fax: +61-3-9496 5663. victorlv@unimelb.edu.au 04 6 2016 2016 04 6 2016 4 39 42 © 2016 The Authors 2016 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials. Keywords PET Tau imaging Alzheimer's disease Positron emission tomography Tauopathies Dementia References 1 Chen-Plotkin A.S. Lee V.M. Trojanowski J.Q. TAR DNA-binding protein 43 in neurodegenerative disease Nat Rev Neurol 6 2010 211 220 20234357 2 Rabinovici G.D. Miller B.L. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management CNS Drugs 24 2010 375 398 20369906 3 Seelaar H. Rohrer J.D. Pijnenburg Y.A. Fox N.C. van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review J Neurol Neurosurg Psychiatry 82 2011 476 486 20971753 4 Klunk W.E. Engler H. Nordberg A. Wang Y. Blomqvist G. Holt D.P. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319 14991808 5 Rowe C.C. Ackerman U. Browne W. Mulligan R. Pike K.L. O'Keefe G. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 7 2008 129 135 18191617 6 Rowe C.C. Pejoska S. Mulligan R.S. Jones G. Chan J.G. Svensson S. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia J Nucl Med 54 2013 880 886 23575995 7 Vandenberghe R. Van Laere K. Ivanoiu A. Salmon E. Bastin C. Triau E. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann Neurol 68 2010 319 329 20687209 8 Wong D.F. Rosenberg P.B. Zhou Y. Kumar A. Raymont V. Ravert H.T. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18) J Nucl Med 51 2010 913 920 20501908 9 Buee L. Bussiere T. Buee-Scherrer V. Delacourte A. Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res Brain Res Rev 33 2000 95 130 10967355 10 Maas T. Eidenmuller J. Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments J Biol Chem 275 2000 15733 15740 10747907 11 Li X. Kumar Y. Zempel H. Mandelkow E.M. Biernat J. Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration EMBO J 30 2011 4825 4837 22009197 12 Hernandez F. Avila J. Tauopathies Cell Mol Life Sci 64 2007 2219 2233 17604998 13 Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies Neuropathology 26 2006 475 483 17080728 14 Zempel H. Luedtke J. Kumar Y. Biernat J. Dawson H. Mandelkow E. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin EMBO J 32 2013 2920 2937 24065130 15 Zempel H. Thies E. Mandelkow E. Mandelkow E.M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines J Neurosci 30 2010 11938 11950 20826658 16 Braak H. Braak E. Evolution of neuronal changes in the course of Alzheimer's disease J Neural Transm Suppl 53 1998 127 140 9700651 17 Delacourte A. David J.P. Sergeant N. Buee L. Wattez A. Vermersch P. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease Neurology 52 1999 1158 1165 10214737 18 Braak H. Braak E. Frequency of stages of Alzheimer-related lesions in different age categories Neurobiol Aging 18 1997 351 357 9330961 19 Serrano-Pozo A. Frosch M.P. Masliah E. Hyman B.T. Neuropathological Alterations in Alzheimer Disease Cold Spring Harb Perspect Med 1 2011 a006189 22229116 20 Guo J.L. Lee V.M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles J Biol Chem 286 2011 15317 15331 21372138 21 Mohorko N. Bresjanac M. Tau Protein And Human Tauopathies: An Overview Zdrav Vestn 77 2008 35 41 22 Lee V.M. Goedert M. Trojanowski J.Q. Neurodegenerative tauopathies Annu Rev Neurosci 24 2001 1121 1159 11520930 23 McKee A.C. Cantu R.C. Nowinski C.J. Hedley-Whyte E.T. Gavett B.E. Budson A.E. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury J Neuropathol Exp Neurol 68 2009 709 735 19535999 24 Masters C.L. Selkoe D.J. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006262 22675658 25 Arriagada P.V. Growdon J.H. Hedley-Whyte E.T. Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 1992 631 639 1549228 26 Rowe C.C. Ng S. Ackermann U. Gong S.J. Pike K. Savage G. Imaging beta-amyloid burden in aging and dementia Neurology 68 2007 1718 1725 17502554 27 McLean C.A. Cherny R.A. Fraser F.W. Fuller S.J. Smith M.J. Beyreuther K. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann Neurol 46 1999 860 866 10589538 28 Zempel H. Mandelkow E.M. Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton Neurodegener Dis 10 2012 64 72 22156588 29 Ittner L.M. Ke Y.D. Gotz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease J Biol Chem 284 2009 20909 20916 19491104 30 Price J.L. Morris J.C. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease Ann Neurol 45 1999 358 368 10072051 31 Villemagne V.L. Fodero-Tavoletti M.T. Pike K.E. Cappai R. Masters C.L. Rowe C.C. The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer's Disease and other Dementias Mol Neurobiol 38 2008 1 15 18690556 32 Jack C.R. Jr. Knopman D.S. Jagust W.J. Petersen R.C. Weiner M.W. Aisen P.S. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216 23332364 33 Jack C.R. Jr. Knopman D.S. Weigand S.D. Wiste H.J. Vemuri P. Lowe V. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease Ann Neurol 71 2012 765 775 22488240 34 Dutra J.R. Cortes E.P. Vonsattel J.P. Update on Hippocampal Sclerosis Curr Neurol Neurosci Rep 15 2015 592 35 Crary J.F. Trojanowski J.Q. Schneider J.A. Abisambra J.F. Abner E.L. Alafuzoff I. Primary age-related tauopathy (PART): a common pathology associated with human aging Acta Neuropathol 128 2014 755 766 25348064 36 Villemagne V.L. Furumoto S. Fodero-Tavoletti M.T. Harada R. Mulligan R.S. Kudo T. The Challenges of Tau Imaging Future Neurol 7 2012 409 421 37 Villemagne V.L. Okamura N. In vivo tau imaging: Obstacles and progress Alzheimers Dement 10 2014 S254 S264 24924676 38 Villemagne V.L. Fodero-Tavoletti M.T. Masters C.L. Rowe C.C. Tau imaging: early progress and future directions Lancet Neurol 14 2015 114 124 25496902 39 Wegmann S. Jung Y.J. Chinnathambi S. Mandelkow E.M. Mandelkow E. Muller D.J. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability J Biol Chem 285 2010 27302 27313 20566652 40 Sergeant N. Bretteville A. Hamdane M. Caillet-Boudin M.L. Grognet P. Bombois S. Biochemistry of Tau in Alzheimer's disease and related neurological disorders Expert Rev Proteomics 5 2008 207 224 18466052 41 Martin L. Latypova X. Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease Neurochem Int 58 2011 458 471 21215781 42 Spillantini M.G. Goedert M. Tau protein pathology in neurodegenerative diseases Trends Neurosci 21 1998 428 433 9786340 43 Rosen R.F. Walker L.C. Levine H. 3rd PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease Neurobiol Aging 32 2011 223 234 19329226 44 Ni R. Gillberg P.G. Bergfors A. Marutle A. Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue Brain 136 2013 2217 2227 23757761 45 Scaravilli T. Tolosa E. Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting Mov Disord 20 Suppl 12 2005 S21 S28 16092076 46 Khatoon S. Grundke-Iqbal I. Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains FEBS Lett 351 1994 80 84 8076698 47 Mukaetova-Ladinska E.B. Harrington C.R. Roth M. Wischik C.M. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease Am J Pathol 143 1993 565 578 8342603 48 Naslund J. Haroutunian V. Mohs R. Davis K.L. Davies P. Greengard P. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 283 2000 1571 1577 10735393 49 Laruelle M. Slifstein M. Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography Mol Imaging Biol 5 2003 363 375 14667491 50 Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism Trends Pharmacol Sci 30 2009 431 440 19616318 51 Villemagne V.L. Klunk W.E. Mathis C.A. Rowe C.C. Brooks D.J. Hyman B.T. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease Eur J Nucl Med Mol Imaging 39 2012 209 219 22218879 52 Shoghi-Jadid K. Small G.W. Agdeppa E.D. Kepe V. Ercoli L.M. Siddarth P. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease Am J Geriatr Psychiatry 10 2002 24 35 11790632 53 Smid L.M. Kepe V. Vinters H.V. Bresjanac M. Toyokuni T. Satyamurthy N. Postmortem 3-D Brain Hemisphere Cortical Tau and Amyloid-beta Pathology Mapping and Quantification as a Validation Method of Neuropathology Imaging J Alzheimers Dis 36 2013 261 274 23568102 54 Taghavi A. Nasir S. Pickhardt M. Heyny-von Haussen R. Mall G. Mandelkow E. N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands J Alzheimers Dis 27 2011 835 843 21891864 55 Jensen J.R. Cisek K. Funk K.E. Naphade S. Schafer K.N. Kuret J. Research towards tau imaging J Alzheimers Dis 26 Suppl 3 2011 147 157 21971459 56 Honson N.S. Johnson R.L. Huang W. Inglese J. Austin C.P. Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules Neurobiol Dis 28 2007 251 260 17761424 57 Kemp S, Storey L, Storey J, Rickard J, Harrington C, Wischik C, inventors; Ligands for aggregated tau molecules. International patent 2010/034982 patent 2010/034982. 2010. 58 Ono M. Hayashi S. Matsumura K. Kimura H. Okamoto Y. Ihara M. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains ACS Chem Neurosci 2 2011 269 275 22778869 59 Watanabe H. Ono M. Kimura H. Matsumura K. Yoshimura M. Okamoto Y. Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease Bioorg Med Chem Lett 22 2012 5700 5703 22832319 60 Matsumura K. Ono M. Yoshimura M. Kimura H. Watanabe H. Okamoto Y. Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease Bioorg Med Chem 21 2013 3356 3362 23601814 61 Bolander A. Kieser D. Voss C. Bauer S. Schon C. Burgold S. Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and beta-amyloid plaques in Alzheimer's disease models J Med Chem 55 2012 9170 9180 22913544 62 Honson N.S. Jensen J.R. Darby M.V. Kuret J. Potent inhibition of tau fibrillization with a multivalent ligand Biochem Biophys Res Commun 363 2007 229 234 17854770 63 Kudo Y, Furumoto S, Okamura N, inventors; Benzoxazole derivatives. U.S. Patent 2010/0021385 patent 2010. 64 Szardenings AK, Zhang W, Kolb HC, Cashion DK, Chen G, Kasi D, et al., inventors; Siemens Medical Solutions USA, Inc., assignee. Imaging Agents for Detecting Neurological Disorders. US Patent 2011/0182812 A1 patent 2011/0182812 A1. 2011. 65 Kudo Y, Susuki M, Suemoto T, Okamura N, Shiomitzu T, Shimazu H, inventors; Quinoline derivative as diagnostic probe for disease with tau protein accumulation. U.S. Patent 7,118,730 patent 2006. 66 Shao X.M. Carpenter G.M. Desmond T.J. Sherman P. Quesada C.A. Fawaz M. Evaluation of [11C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles ACS Med Chem Lett 3 2012 936 941 24900410 67 Fawaz M.V. Brooks A.F. Rodnick M.E. Carpenter G.M. Shao X. Desmond T.J. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection ACS Chem Neurosci 5 2014 718 730 24896980 68 Maruyama M. Shimada H. Suhara T. Shinotoh H. Ji B. Maeda J. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls Neuron 79 2013 1094 1108 24050400 69 Hashimoto H. Kawamura K. Igarashi N. Takei M. Fujishiro T. Aihara Y. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology J Nucl Med 55 2014 1532 1538 24963128 70 Xia C.F. Arteaga J. Chen G. Gangadharmath U. Gomez L.F. Kasi D. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease Alzheimers Dement 9 2013 666 676 23411393 71 Chien D.T. Bahri S. Szardenings A.K. Walsh J.C. Mu F. Su M.Y. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807 J Alzheimers Dis 34 2013 457 468 23234879 72 Vieira M. Saraiva M.J. Transthyretin: a multifaceted protein Biomol Concepts 5 2014 45 54 25372741 73 Johnson K.A. Schultz A. Betensky R.A. Becker J.A. Sepulcre J. Rentz D. Tau positron emission tomographic imaging in aging and early Alzheimer disease Ann Neurol 79 2016 110 119 26505746 74 Okamura N. Suemoto T. Furumoto S. Suzuki M. Shimadzu H. Akatsu H. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease J Neurosci 25 2005 10857 10862 16306398 75 Okamura N. Furumoto S. Harada R. Tago T. Yoshikawa T. Fodero-Tavoletti M. Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease J Nucl Med 54 2013 1420 1427 23857514 76 Fodero-Tavoletti M.T. Okamura N. Furumoto S. Mulligan R.S. Connor A.R. McLean C.A. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease Brain 134 2011 1089 1100 21436112 77 Harada R. Okamura N. Furumoto S. Tago T. Maruyama M. Higuchi M. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology Eur J Nucl Med Mol Imaging 40 2013 125 132 23100049 78 Fodero-Tavoletti M.T. Furumoto S. Taylor L. McLean C.A. Mulligan R.S. Birchall I. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies Alzheimers Res Ther 6 2014 11 24572336 79 Villemagne V.L. Furumoto S. Fodero-Tavoletti M.T. Mulligan R.S. Hodges J. Harada R. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease Eur J Nucl Med Mol Imaging 41 2014 816 826 24514874 80 Okamura N. Furumoto S. Fodero-Tavoletti M.T. Mulligan R.S. Harada R. Yates P. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET Brain 137 2014 1762 1771 24681664 81 Villemagne V.L. Burnham S. Bourgeat P. Brown B. Ellis K.A. Salvado O. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367 23477989 82 Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model Science 316 2007 750 754 17478722 83 Giacobini E. Becker R.E. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J Alzheimers Dis 12 2007 37 52 17851193 84 Zhang B. Maiti A. Shively S. Lakhani F. McDonald-Jones G. Bruce J. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model Proc Natl Acad Sci U S A 102 2005 227 231 15615853 85 Wischik C. Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy J Nutr Health Aging 13 2009 367 369 19300883 86 Duyckaerts C. Braak H. Brion J.P. Buee L. Del Tredici K. Goedert M. PART is part of Alzheimer disease Acta Neuropathol 129 2015 749 756 25628035 87 Jellinger K.A. Alafuzoff I. Attems J. Beach T.G. Cairns N.J. Crary J.F. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease Acta Neuropathol 129 2015 757 762 25778618 Supplementary data Video Reference mentioned in this video article can be found here. Acknowledgments We thank Professors Yukitsuda Kudo, Colin Masters, Kazuhiko Yanai, Shozo Furumoto, Drs Ryuichi Harada, Michelle Fodero-Tavoletti, William P. Blatty, Mrs Svetlana Pejoska-Bozinovski, Ms Fiona Lamb, and the Brain Research Institute for their assistance with this study. This review was supported in part by NHMRC Project Grant 1044361. VLV is supported by NHMRC Research Fellowship 1046471. The funding sources had no input into the design of this study, the analysis of data, or writing of the manuscript. V.L.V. has received speaker honoraria from GE Healthcare, Piramal Imaging, and Avid Radiopharmaceuticals and consulting honoraria from Novartis and Lundbeck. N.O. has received research support from Clino Co. Ltd. THK compounds have been licensed to GE Healthcare. C.C.R. has received speaker honoraria from received speaker and consulting honoraria from GE Healthcare, Piramal Imaging, Avid Radiopharmaceuticals, Navidea, and AstraZeneca. Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.dadm.2016.05.001 .",
  "plain_text": "In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials."
}
